Key Highlights

  • iPerionX shares dropped 9.14% to $3.68 with trading volume 144% above the 90-day average, extending the recent sharp selloff as markets reprice the growth narrative.
  • The company has secured over $99 million in committed US government funding to support its proprietary titanium production technology, including a $47.1 million IBAS award from the Department of Defense.
  • H1 2026 net loss more than doubled to US$34.77 million from US$16.24 million, reflecting heavy reinvestment while revenue remains minimal.
  • The Virginia manufacturing campus has achieved commercial commissioning with capacity expanded from 125 to 200 tonnes per annum, targeting 1,400 tonnes per annum by mid-2027.

iPerionX Limited (ASX:IPX) continues to face intense selling pressure, with shares falling 9.14% to AUD 3.68 on volume 144% above the 90-day average (as on 19 March 2026). The decline extends a brutal correction that has seen the stock plunge approximately 42% from its recent March high of $6.93 in just a handful of trading sessions.

The selloff reflects a fundamental market repricing of iPerionX's growth story. While the company's proprietary titanium production technology and US government backing remain compelling long-term catalysts, accelerating losses and minimal revenue have forced investors to reassess the timeline to commercial viability.

For those tracking IPX stock analysis and share price outlook, this represents a critical inflection point where the bull and bear cases are most actively debated.

About iPerionX Limited

iPerionX is a critical minerals and advanced titanium metal company developing integrated domestic titanium production infrastructure in the United States. The company operates through two core platforms: the Virginia Titanium Manufacturing Campus for commercial-scale production of titanium powders and components, and the Titan Critical Minerals Project in Tennessee for mineral extraction.

The company's proprietary HAMR technology offers a potentially lower-cost and lower-carbon alternative to the 70-year-old Kroll process that dominates the titanium industry. Target markets include aerospace and defence, automotive, consumer electronics, medical devices, and additive manufacturing.

Competitive advantages include strong US government support with over $99 million in committed funding, vertical integration from raw minerals through finished components, and alignment with national security priorities for domestic critical mineral supply chains.

Why IPX Stock Is Falling Today

The 9.14% decline with elevated volume reflects continued market repricing following the H1 2026 results that showed net losses more than doubling to US$34.77 million. This acceleration in cash burn occurred despite the Virginia campus reaching commercial commissioning, raising questions about the revenue timeline.

The broader context of ASX volatility driven by geopolitical tensions, rising bond yields, and rate hike expectations has amplified selling in high-growth, pre-revenue stocks like iPerionX.

Industry Trends

The titanium market fundamentals support long-term demand growth. The titanium dioxide market is valued at $24 billion in 2024 with projections reaching $33 billion by 2030. Rising global defence spending, expanding aerospace production, and growing additive manufacturing adoption drive demand for high-quality titanium products.

US government policy strongly favours domestic critical mineral production. The Department of Defense's IBAS program, Defense Production Act funding, and broader supply chain resilience initiatives create a supportive environment for companies like iPerionX.

However, the Kroll process remains deeply entrenched as the industry standard. Previous attempts to commercialise alternative titanium production technologies have failed, creating justified scepticism about HAMR's ability to achieve commercial scale.

Financial Performance

iPerionX remains pre-revenue with accelerating losses. FY2025 operating loss widened to US$38.33 million, while H1 2026 net loss reached US$34.77 million, more than double the prior year's US$16.24 million.

Total assets have grown to US$105.03 million, reflecting significant capital investment in manufacturing infrastructure. Shareholder equity stands at $92.44 million with minimal debt.

The cash runway is sufficient for more than one year based on current burn rates, but the estimated US$75 million needed for the 1,400 tonnes per annum expansion suggests future capital raises are likely, potentially diluting existing shareholders.

Investment Risks

Valuation is the most immediate concern. The stock has been trading at extreme multiples relative to specialty metals industry medians, with potential for significant further downside if revenue materialisation continues to lag.

Technology risk is material. While HAMR is promoted as industry-changing, it remains unproven at commercial scale. The Kroll process has a 70-year track record, and previous displacement attempts have uniformly failed.

Ongoing losses and cash burn create continuous funding pressure. Future capital raises would dilute existing shareholders and could pressure the stock price. Management credibility concerns raised by short sellers add governance risk.

Customer adoption remains unproven with no major long-term contracts secured, meaning revenue projections remain speculative.

Future Growth Drivers

The Titan Critical Minerals Project Definitive Feasibility Study completion expected in Q2 2026 could unlock project financing and validate mine economics. Virginia campus expansion to 1,400 tonnes per annum by mid-2027 would position iPerionX as a significant US titanium producer.

Defence contracts continue to build, including a $0.3 million order from American Rheinmetall for 700 lightweight titanium components. US Army and Navy engagement provides validation of the technology's potential.

Rare earth extraction capability from the Titan project could add strategic value, potentially supplying domestic dysprosium and terbium for defence electronics.

Conclusion

iPerionX's 42% correction reflects a necessary repricing of expectations as the market transitions from valuing the story to demanding execution evidence. The company's strategic positioning in US critical minerals with $99 million in government support remains compelling, but the path from concept to commercial scale is fraught with risk. Investors should approach IPX as a speculative position with asymmetric upside if technology and commercial milestones are achieved, balanced against meaningful downside if execution falters.

Questions Investors Are Asking About iPerionX

Q: Why is IPX stock falling today?

A: IPX dropped 9.14% on continued repricing of the growth story following H1 2026 losses more than doubling, recent analyst price target reductions, and broader market volatility affecting pre-revenue growth stocks.

Q: Is iPerionX a good investment?

A: IPX is a high-risk, high-reward speculative play on US critical minerals policy and titanium technology disruption. The $99 million in government funding provides support, but accelerating losses and unproven commercial viability create significant uncertainty.

Q: What is HAMR technology?

A: HAMR is iPerionX's proprietary hydrogen-based titanium production process that reportedly offers lower cost and carbon footprint compared to the traditional Kroll process. It remains unproven at commercial scale.

Q: What are the growth prospects?

A: Near-term catalysts include the Titan DFS in Q2 2026 and Virginia campus expansion to 1,400 tonnes per annum by mid-2027. Long-term potential exists if HAMR technology achieves commercial validation.

Q: What are the biggest risks?

A: Key risks include unproven technology at scale, accelerating losses, potential shareholder dilution, minimal revenue and customer contracts, and governance concerns raised by short sellers.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research and consult with qualified financial advisors before making investment decisions. Past performance is not indicative of future results.